Form 4: ENDRA Life Sciences Director Receives Equity Grant

ENDRA Life Sciences Director Michael Harsh was granted 60,324 restricted stock units, vesting in January 2026.

Summary

• Michael Harsh, a Director of ENDRA Life Sciences Inc. (NDRA), acquired 60,324 restricted stock units (RSUs).
• The transaction date for this acquisition was January 21, 2026.
• These RSUs convert to common stock on a one-for-one basis and will vest in full on January 21, 2026.
• The acquisition price for these RSUs was $0, which is typical for equity grants.
• Following this transaction, Michael Harsh beneficially owns a total of 65,710 shares of common stock, which includes these unvested RSUs.

Sentiment

Score: 6

Explanation: The filing reports a routine equity compensation event for a director, which is a neutral to slightly positive development as it aligns interests with shareholders. It does not contain information that would significantly alter the company's financial outlook or operational status.

Positives

• The grant of restricted stock units to a director aligns management's interests with those of shareholders, incentivizing long-term company performance.

Future Outlook

The restricted stock units granted to Director Michael Harsh are scheduled to vest in full on January 21, 2026, converting into common stock.

Industry Context

The granting of restricted stock units (RSUs) to directors is a common practice in publicly traded companies to attract, retain, and incentivize key personnel by aligning their financial interests with long-term shareholder value.

Comparison to Industry Standards

• Equity compensation, particularly through restricted stock units, is a standard component of director remuneration across various industries, including life sciences.
• The grant of 60,324 RSUs to a director is within typical ranges for companies of similar market capitalization and stage, aiming to provide meaningful incentive without excessive dilution.

Stakeholder Impact

• Shareholders: The grant of RSUs to a director helps align the director's long-term interests with those of the shareholders, potentially fostering better governance and strategic decisions aimed at increasing shareholder value.

Next Steps

• The restricted stock units will vest in full on January 21, 2026, at which point they will convert into common stock.

Key Dates

Keywords

ENDRA Life Sciences, NDRA, Form 4, Restricted Stock Units, RSU, Director Compensation, Equity Grant, Beneficial Ownership